Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Ravaud

Showing results (41-50 of 221) with videos related to

Pageof 23
Sort By:
Immunotherapy|April 28, 2021
Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapyCharlotte Domblides, Marine Gross-Goupil, Alain Ravaud, et al.
Urology|August 12, 2008
Combined radiofrequency ablation and antiangiogenic drug for the treatment of recurrent renal tumorNicolas Grenier, Catherine Douws, Vincent Pérot, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2020
Adaptation of multidisciplinary meeting decisions in a medical oncology department during the COVID epidemic in a less affected region of France: a prospective analysis from Bordeaux University HospitalLuc Heraudet, Charlotte Domblides, Amaury Daste, et al.
Tumori|October 29, 2002
Symptomatic neurological epidural metastasis with interleukin-2 therapy in metastatic renal cell carcinomaNathalie Trufflandier, Olivier Gille, Jean Palussière, et al.
Archivos Espanoles De Urologia|November 25, 2010
Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancerHervé Wallerand, Grégoire Robert, Jean-Christophe Bernhard, et al.
Bulletin Du Cancer|December 17, 2008
[Prostate carcinoma in the elderly]Alain Ravaud, Gilles Pasticier, Jean-Louis Davin, et al.
Targeted Oncology|January 4, 2013
Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literatureAmaury Daste, Marine Gross-Goupil, Sophie Roca, et al.
Expert Opinion on Biological Therapy|July 10, 2019
Which place for avelumab in the management of urothelial carcinoma?Mathieu Larroquette, Marine Gross-Goupil, Amaury Daste, et al.
Oral Oncology|September 4, 2016
m-TOR inhibitor as potential radiosensitizer for head and neck squamous cell carcinoma: A case report of an organ transplant patient and review of the literatureAmaury Daste, Erwan de Mones, Charles Dupin, et al.
Clinical Genitourinary Cancer|May 30, 2017
Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the LiteraturePauline Bertolaso, Marine Gross-Goupil, Mathieu Molimard, et al.
Pageof 23

Showing results (41-50 of 221) with videos related to

Sort By:
Pageof 23
Immunotherapy|April 28, 2021
Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapyCharlotte Domblides, Marine Gross-Goupil, Alain Ravaud, et al.
Urology|August 12, 2008
Combined radiofrequency ablation and antiangiogenic drug for the treatment of recurrent renal tumorNicolas Grenier, Catherine Douws, Vincent Pérot, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2020
Adaptation of multidisciplinary meeting decisions in a medical oncology department during the COVID epidemic in a less affected region of France: a prospective analysis from Bordeaux University HospitalLuc Heraudet, Charlotte Domblides, Amaury Daste, et al.
Tumori|October 29, 2002
Symptomatic neurological epidural metastasis with interleukin-2 therapy in metastatic renal cell carcinomaNathalie Trufflandier, Olivier Gille, Jean Palussière, et al.
Archivos Espanoles De Urologia|November 25, 2010
Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancerHervé Wallerand, Grégoire Robert, Jean-Christophe Bernhard, et al.
Bulletin Du Cancer|December 17, 2008
[Prostate carcinoma in the elderly]Alain Ravaud, Gilles Pasticier, Jean-Louis Davin, et al.
Targeted Oncology|January 4, 2013
Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literatureAmaury Daste, Marine Gross-Goupil, Sophie Roca, et al.
Expert Opinion on Biological Therapy|July 10, 2019
Which place for avelumab in the management of urothelial carcinoma?Mathieu Larroquette, Marine Gross-Goupil, Amaury Daste, et al.
Oral Oncology|September 4, 2016
m-TOR inhibitor as potential radiosensitizer for head and neck squamous cell carcinoma: A case report of an organ transplant patient and review of the literatureAmaury Daste, Erwan de Mones, Charles Dupin, et al.
Clinical Genitourinary Cancer|May 30, 2017
Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the LiteraturePauline Bertolaso, Marine Gross-Goupil, Mathieu Molimard, et al.
Pageof 23